Peer-reviewed veterinary case report
Tumor markers in benign and malignant dog mammary tumors
By Günay Uçmak, Zeynep et al.·Published in Acta veterinaria Hungarica·2025·Department of Obstetrics and Gynaecology·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Investigation of some tumour biomarkers in canine mammary tumours related to clinicopathological parameters.
- Species:
- dog
Plain-English summary
A study looked at mammary tumors in dogs to understand how certain biomarkers relate to whether the tumors are benign or malignant. Researchers examined tissue samples from 22 dogs and found that levels of estrogen and epidermal growth factor receptors were higher in benign tumors compared to malignant ones. The study also indicated that the progesterone receptor could help differentiate between more aggressive tumors. These findings suggest that testing for these biomarkers might help veterinarians assess the nature of mammary tumors in dogs and guide treatment decisions.
People also search for: dog mammary tumor treatment · canine breast cancer symptoms · dog tumor biomarkers
Abstract
The aim of this study is to evaluate the differences in tissue levels of oestrogen receptor (ER), progesterone receptor (PR), epidermal growth factor receptor (EGFR) and carbohydrate antigen 15-3 (CA 15-3) in benign and malignant mammary tumours in dogs. A total of 45 tumoural masses taken from 22 dogs with mammary tumours were included in the study. Based on the histopathological results of mammary tissues, study groups were formed as bening tumours (Group BT; n = 15) and malignant tumours (Group MT; n = 30) with Group MT divided into 2 subgroups as malignant epithelial tumours (Group MET; n = 16), carcinosarcomas and malignant mixed tumours (Group MMT; n = 14). Mean ER and EGFR levels in Group BT were significantly higher than both in Group MT (P < 0.01) and Group MET (P < 0.05). In Group MET, only PR levels exhibited significant differences related to the clinicopathological parameters. In conclusion, with the PR biomarker, a distinction can be made between Grade 2 and Grade 3 tumours and invasive or non-invasive tumours. It has been observed that these biomarkers can reveal the presence of the tumour and may be beneficial in evaluating the clinical and pathological characteristics of the tumour.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40892468/